- Home
- SUPV vs PCRX Comparison
SUPV vs PCRX Comparison
Compare SUPV & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPV | PCRX |
|---|---|---|
| Founded | 1887 | 2006 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 951.9M | 1.0B |
| IPO Year | 2016 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SUPV | PCRX |
|---|---|---|
| Price | $10.57 | $21.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $13.33 | ★ $35.33 |
| AVG Volume (30 Days) | ★ 1.1M | 833.4K |
| Earning Date | 03-09-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $396,684,246.00 | ★ $716,791,000.00 |
| Revenue This Year | $12.75 | $6.21 |
| Revenue Next Year | $45.23 | $8.26 |
| P/E Ratio | ★ N/A | $46.19 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $4.54 | $18.80 |
| 52 Week High | $17.02 | $27.64 |
Technical Indicators
Market Signals| Indicator | SUPV | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 51.52 |
| Support Level | $10.22 | $20.88 |
| Resistance Level | $12.14 | $22.09 |
| Average True Range (ATR) | 0.77 | 0.76 |
| MACD | -0.09 | 0.30 |
| Stochastic Oscillator | 18.67 | 90.52 |
Price Performance
Historical ComparisonAbout SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.